HUP0302119A3 - Use of baculovirus vectors in gene therapy - Google Patents

Use of baculovirus vectors in gene therapy

Info

Publication number
HUP0302119A3
HUP0302119A3 HU0302119A HUP0302119A HUP0302119A3 HU P0302119 A3 HUP0302119 A3 HU P0302119A3 HU 0302119 A HU0302119 A HU 0302119A HU P0302119 A HUP0302119 A HU P0302119A HU P0302119 A3 HUP0302119 A3 HU P0302119A3
Authority
HU
Hungary
Prior art keywords
gene therapy
baculovirus vectors
baculovirus
vectors
therapy
Prior art date
Application number
HU0302119A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of HUP0302119A2 publication Critical patent/HUP0302119A2/hu
Publication of HUP0302119A3 publication Critical patent/HUP0302119A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU0302119A 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy HUP0302119A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery
PCT/GB2001/002383 WO2001090390A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Publications (2)

Publication Number Publication Date
HUP0302119A2 HUP0302119A2 (hu) 2003-09-29
HUP0302119A3 true HUP0302119A3 (en) 2005-12-28

Family

ID=9892534

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302119A HUP0302119A3 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Country Status (13)

Country Link
EP (1) EP1283894A1 (ja)
JP (1) JP2003533992A (ja)
KR (1) KR20030072213A (ja)
CN (1) CN1430675A (ja)
AU (1) AU2001258657A1 (ja)
CA (1) CA2413326A1 (ja)
GB (1) GB0012997D0 (ja)
HU (1) HUP0302119A3 (ja)
IL (1) IL153070A0 (ja)
MX (1) MXPA02011517A (ja)
NO (1) NO20025657L (ja)
PL (1) PL360280A1 (ja)
WO (1) WO2001090390A1 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008541769A (ja) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
ES2465473T3 (es) 2006-09-08 2014-06-05 Ambrx, Inc. Transcripción de arnt supresor en células de vertebrado
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
CN101358204B (zh) * 2008-08-29 2011-05-18 浙江理工大学 一种重组杆状病毒感染后细胞膜及细胞器膜蛋白的制备方法
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
PL3412302T3 (pl) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Zmodyfikowane polipeptydy fgf-21 i ich zastosowania
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN114736929B (zh) * 2022-05-16 2023-06-09 睿征医药科技(武汉)有限公司 一种用于昆虫细胞中产生重组杆状病毒的组合物、方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE287271T1 (de) * 1996-11-01 2005-02-15 Ark Therapeutics Ltd Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät
DE19735593C2 (de) * 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
EP1100946A1 (fr) * 1998-07-24 2001-05-23 Aventis Pharma S.A. Vecteurs derives de baculorivus et utilisation pour le transfert d'acides nucleiques dans les cellules nerveuses des vertebres

Also Published As

Publication number Publication date
JP2003533992A (ja) 2003-11-18
NO20025657D0 (no) 2002-11-25
KR20030072213A (ko) 2003-09-13
CA2413326A1 (en) 2001-11-29
MXPA02011517A (es) 2004-01-26
EP1283894A1 (en) 2003-02-19
NO20025657L (no) 2002-11-25
CN1430675A (zh) 2003-07-16
WO2001090390A9 (en) 2003-01-09
HUP0302119A2 (hu) 2003-09-29
IL153070A0 (en) 2003-06-24
WO2001090390A1 (en) 2001-11-29
GB0012997D0 (en) 2000-07-19
PL360280A1 (en) 2004-09-06
AU2001258657A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
HUP0302119A3 (en) Use of baculovirus vectors in gene therapy
IL152549A0 (en) Vectors for ocular transduction and use thereof for genetic therapy
AU1194802A (en) DNA expression vectors and methods of use
AU2002367262A8 (en) Personal user agent
GB0004003D0 (en) Therapeutic agents
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
GB0005789D0 (en) Therapeutic agents
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
GB0000564D0 (en) Therapeutic agents
GB0119025D0 (en) Compounds and their therapeutic use
EP1317271A4 (en) THERAPEUTIC AND COSMETIC USES OF HEPARANASES
GB0018887D0 (en) Compound and their therapeutic use
GB0008966D0 (en) Vectors for gene therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
TW423322U (en) Improved structure of massage pad
GB0017625D0 (en) Use of compounds in therapy
GB0012945D0 (en) Use of compounds in therapy
GB0030058D0 (en) Use of compounds in therapy
GB0024614D0 (en) Massage manipulation ball
GB0017028D0 (en) Peptides and their therapeutic use
GB0118627D0 (en) Use of compounds in therapy
GB0023473D0 (en) Therapeutic use and formulation
GB0018885D0 (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees